Literature DB >> 26515749

Childhood posterior reversible encephalopathy syndrome: Magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal.

Ajay Agarwal1, Gaurav Kapur2, Deniz Altinok3.   

Abstract

PURPOSE: Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic syndrome characterized clinically by headache, seizures, and altered sensorium and radiological changes which are usually reversible. The purpose of this study was to describe the spectrum of magnetic resonance imaging (MRI) findings in childhood PRES, to determine the common etiologies for childhood PRES, and to have an insight into the pathophysiology of PRES.
METHODS: The MRI results of 20 clinically diagnosed cases of PRES between July 2011 and June 2013 were reviewed. The final diagnosis of PRES was based on the clinical presentation and the MRI features at the time of presentation, which resolved on the follow-up imaging. The medical records of the patients were reviewed to determine the underlying medical disease.
RESULTS: Eight out of the 20 patients included in the study were on cyclosporine or tacrolimus based immunosuppressant therapy for kidney transplant. Four patients had severe hypertension at presentation. The most common MRI finding was high T2-fluid-attenuated inversion recovery (FLAIR) signal in the cortex and subcortical white matter of both cerebral hemispheres, particularly in the parietal and occipital lobes (n=16). The second most common MRI finding was increased leptomeningeal FLAIR signal (n=7). Out of seven patients with leptomeningeal signal, five demonstrated leptomeningeal enhancement as well. Four out of these seven patients had no other parenchymal findings.
CONCLUSION: Childhood PRES is commonly seen in the setting of immunosuppressant therapy for kidney transplant, severe hypertension and cancer treatment. There was high incidence of increased leptomeningeal FLAIR signal and leptomeningeal enhancement in our study. It supports the current theory of endothelial injury with increased microvascular permeability as the potential pathophysiology of PRES. Also, absence of elevated blood pressure in majority of the patients in our study supports the theory of direct endothelial injury by some agents leading to vasogenic edema.
© The Author(s) 2015.

Entities:  

Keywords:  Magnetic resonance imaging; childhood; encephalopathy; posterior reversible encephalopathy syndrome

Mesh:

Substances:

Year:  2015        PMID: 26515749      PMCID: PMC4757130          DOI: 10.1177/1971400915609338

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  19 in total

1.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging.

Authors:  Lauren M Brubaker; J Keith Smith; Yueh Z Lee; Weili Lin; Mauricio Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Brain in eclampsia: MR imaging with clinical correlation.

Authors:  T G Sanders; D A Clayman; L Sanchez-Ramos; F S Vines; L Russo
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

4.  Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases.

Authors:  R B Schwartz; K M Jones; P Kalina; R L Bajakian; M T Mantello; B Garada; B L Holman
Journal:  AJR Am J Roentgenol       Date:  1992-08       Impact factor: 3.959

5.  Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia.

Authors:  P W Schaefer; F S Buonanno; R G Gonzalez; L H Schwamm
Journal:  Stroke       Date:  1997-05       Impact factor: 7.914

6.  Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity.

Authors:  W S Bartynski; B C Grabb; Z Zeigler; L Lin; D F Andrews
Journal:  J Comput Assist Tomogr       Date:  1997 Nov-Dec       Impact factor: 1.826

7.  Unusual MR findings of the brain stem in arterial hypertension.

Authors:  J de Seze; B Mastain; T Stojkovic; D Ferriby; J P Pruvo; A Destée; P Vermersch
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

8.  MR imaging of reversible cyclosporin A-induced neurotoxicity.

Authors:  C L Truwit; C P Denaro; J R Lake; T DeMarco
Journal:  AJNR Am J Neuroradiol       Date:  1991 Jul-Aug       Impact factor: 3.825

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

10.  MR angiography of cerebral vasospasm in preeclampsia.

Authors:  T Ito; T Sakai; S Inagawa; M Utsu; T Bun
Journal:  AJNR Am J Neuroradiol       Date:  1995 Jun-Jul       Impact factor: 3.825

View more
  3 in total

1.  Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section Part II: Trigeminal and facial nerve schwannomas (CN V, VII).

Authors:  Jarnail Bal; Michael Bruneau; Moncef Berhouma; Jan F Cornelius; Luigi M Cavallo; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Torstein R Meling; Mahmoud Messerer; Pierre-Hugues Roche; Henry W S Schroeder; Marcos Tatagiba; Idoya Zazpe; Dimitrios Paraskevopoulos
Journal:  Acta Neurochir (Wien)       Date:  2022-01-25       Impact factor: 2.216

2.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 3.  Paediatric brainstem: A comprehensive review of pathologies on MR imaging.

Authors:  Chandan Kakkar; Shruti Kakkar; Kavita Saggar; Jatinder S Goraya; Archana Ahluwalia; Ankur Arora
Journal:  Insights Imaging       Date:  2016-05-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.